Literature DB >> 28247082

Membrane pressures predict clotting of pediatric continuous renal replacement therapy circuits.

Aadil Kakajiwala1,2, Thomas Jemielita3, John Z Hughes4, Kimberly Windt5, Michelle Denburg5, Stuart L Goldstein6, Benjamin Laskin5.   

Abstract

BACKGROUND: Clotting of continuous renal replacement therapy (CRRT) circuits leads to inadequate clearance, decreased ultrafiltration, and increased resource use. We identified factors associated with premature clotting of circuits during CRRT in children.
METHODS: In a retrospective cohort of 26 children (median age 11.8 years) receiving 79 CRRT circuits (51 heparin, 22 citrate, 6 using no anticoagulation), we captured hourly pressure, flow, and fluid removal rates along with all activated clotting time (ACT) and circuit ionized calcium measurements. Cox and logistic regression models were used to examine factors associated with premature circuit clotting before the scheduled 3-day circuit change.
RESULTS: Of the 79 circuits, 51 (64.6%) underwent unplanned filter change due to filter clotting (median duration 18.25 h, interquartile range [IQR] 9.25, 33.5 h), and 28 (35.4%) underwent scheduled change (median duration 66 h, IQR 61.00, 69.00 h). Patient age, catheter size and location, blood flow rate, and the percentage of pre-filter replacement fluid were not associated with premature clotting. Heparin circuits were less likely than citrate circuits to clot prematurely. Each 1-mmHg increase in the transmembrane or filter pressure was independently associated with a 1.5% (95% confidence interval [CI] 1.0-2.0%) and 1.5% (95% CI 1.0-2.0%) higher risk of clotting, respectively. Higher ACTs were associated with lower transmembrane (p = 0.03) and filter (p < 0.001) pressures.
CONCLUSIONS: The majority of circuits in our cohort were subject to unplanned filter changes. Elevated transmembrane and filter pressures were associated with clotting. Our results suggest that maintaining higher ACT may decrease the risk of circuit clotting. Larger studies are needed to examine other factors that may prolong the lifespan of the CRRT circuit in this high-risk population.

Entities:  

Keywords:  Anticoagulation; Continuous renal replacement therapy; Filter clotting; Membrane pressures; Pediatrics

Mesh:

Substances:

Year:  2017        PMID: 28247082      PMCID: PMC5441937          DOI: 10.1007/s00467-017-3601-z

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  24 in total

1.  Factors affecting system clotting in continuous renal replacement therapy: results of a randomized, controlled trial.

Authors:  G V Ramesh Prasad; P M Palevsky; R Burr; J M Lesko; B Gupta; A Greenberg
Journal:  Clin Nephrol       Date:  2000-01       Impact factor: 0.975

2.  Continuous renal replacement therapy in critically ill patients: monitoring circuit function.

Authors:  A W Holt; P Bierer; A D Bersten; L K Bury; A E Vedig
Journal:  Anaesth Intensive Care       Date:  1996-08       Impact factor: 1.669

Review 3.  Continuous renal replacement therapy in children.

Authors:  Scott M Sutherland; Steven R Alexander
Journal:  Pediatr Nephrol       Date:  2012-02-28       Impact factor: 3.714

Review 4.  Continuous renal-replacement therapy for acute kidney injury.

Authors:  Ashita Tolwani
Journal:  N Engl J Med       Date:  2012-12-27       Impact factor: 91.245

5.  Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study.

Authors:  Mehran Monchi; Denis Berghmans; Didier Ledoux; Jean-Luc Canivet; Bernard Dubois; Pierre Damas
Journal:  Intensive Care Med       Date:  2003-11-05       Impact factor: 17.440

6.  Demographic characteristics of pediatric continuous renal replacement therapy: a report of the prospective pediatric continuous renal replacement therapy registry.

Authors:  Jordan M Symons; Annabelle N Chua; Michael J G Somers; Michelle A Baum; Timothy E Bunchman; Mark R Benfield; Patrick D Brophy; Douglas Blowey; James D Fortenberry; Deepa Chand; Francisco X Flores; Richard Hackbarth; Steven R Alexander; John Mahan; Kevin D McBryde; Stuart L Goldstein
Journal:  Clin J Am Soc Nephrol       Date:  2007-05-18       Impact factor: 8.237

Review 7.  Acute kidney injury in children: an update on diagnosis and treatment.

Authors:  James D Fortenberry; Matthew L Paden; Stuart L Goldstein
Journal:  Pediatr Clin North Am       Date:  2013-03-13       Impact factor: 3.278

8.  Citrate anticoagulation for continuous renal replacement therapy in small children.

Authors:  Jolanta Soltysiak; Alfred Warzywoda; Bartłomiej Kociński; Danuta Ostalska-Nowicka; Anna Benedyk; Magdalena Silska-Dittmar; Jacek Zachwieja
Journal:  Pediatr Nephrol       Date:  2013-12-13       Impact factor: 3.714

9.  Circuit life span in critically ill children on continuous renal replacement treatment: a prospective observational evaluation study.

Authors:  Jimena del Castillo; Jesús López-Herce; Elena Cidoncha; Javier Urbano; Santiago Mencía; Maria J Santiago; Jose M Bellón
Journal:  Crit Care       Date:  2008-07-25       Impact factor: 9.097

Review 10.  Clinical review: Patency of the circuit in continuous renal replacement therapy.

Authors:  Michael Joannidis; Heleen M Oudemans-van Straaten
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

View more
  2 in total

1.  Anticoagulation in patients with acute kidney injury undergoing kidney replacement therapy.

Authors:  Rupesh Raina; Ronith Chakraborty; Andrew Davenport; Patrick Brophy; Sidharth Sethi; Mignon McCulloch; Timothy Bunchman; Hui Kim Yap
Journal:  Pediatr Nephrol       Date:  2021-10-19       Impact factor: 3.651

Review 2.  Regional Citrate Anticoagulation and Systemic Anticoagulation during Pediatric Continuous Renal Replacement Therapy: A Systematic Literature Review.

Authors:  Emanuele Buccione; Stefano Bambi; Laura Rasero; Lorenzo Tofani; Tessa Piazzini; Carlo Della Pelle; Khadija El Aoufy; Zaccaria Ricci; Stefano Romagnoli; Gianluca Villa
Journal:  J Clin Med       Date:  2022-05-31       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.